To evaluate the real-world efficacy and safety of adalimumab (ADA) combined with conventional therapy in patients with chronic non-infectious anterior uveitis (NIAU). This retrospective cohort study included 114 patients with chronic NIAU treated at a single tertiary center between May 2022 and May 2025. Patients were divided into a study group receiving ADA plus conventional therapy (n = 58) and a control group receiving conventional therapy alone (n = 56). Anterior chamber (AC) cell count, best-corrected visual acuity (BCVA), treatment response, adjunctive therapy use, complications and adverse events were compared over 6 months. Multivariate logistic regression was performed to identify factors associated with complete remission. At 3 and 6 months, the ADA group showed significantly lower AC cell counts and greater BCVA improvement than controls (all P < 0.05). At 6 months, complete remission was achieved in 84.5% of the ADA group versus 64.3% of controls, with lower relapse rates (13.8% vs. 28.6%, both P < 0.05). After adjustment, ADA use was independently associated with complete remission (adjusted OR = 2.85, 95% CI 1.15-7.05). The ADA group required less adjunctive corticosteroid and immunosuppressive therapy and had lower rates of cataract and ocular hypertension. Most adverse events were mild, with one serious infection leading to discontinuation. In real-world practice, adalimumab combined with conventional therapy is associated with improved inflammation control, visual outcomes and reduced relapse in chronic NIAU, with an acceptable safety profile.

To examine the differences between non-Hispanic White patients and other racial/ethnic groups and their likelihood of concurrent diagnosis with non-infectious anterior uveitis (AU) and other ocular conditions. The TriNetX database was used to identify adult patients with an incident diagnosis of non-infectious AU using ICD-10 codes. Non-Hispanic White patients with AU were compared to three groups (non-White, Black, and Hispanic patients). Odds ratios and 95% CIs for ocular conditions at the time of diagnosis with AU were compared between cohorts to evaluate the likelihood of a concurrent diagnosis with another ocular condition. In the first group, Non-Hispanic White patients had greater odds of legal blindness (OR: 1.994; 95% CI: 1.5882.503) and epiretinal membrane (OR: 1.794; 95% CI: 1.514-2.126) compared to non-White patients. In the second group, Non-Hispanic White patients had lower odds of glaucoma (OR: 0.853; 95% CI: 0.805-0.904), glaucoma suspect (OR: 0.797; 95% CI: 0.735-0.864), and open angle glaucoma (OR: 0.53; 95% CI: 0.460-0.611) compared to Black patients. In the third group, Non-Hispanic White patients had lower odds of cataracts (OR: 0.755; 95% CI: 0.604-0.945), glaucoma (OR:0.706; 95% CI: 0.574-0.868), and glaucoma suspect (OR: 0.743; 95% CI: 0.557 -0.991) compared to Hispanic patients. Non-Hispanic White patients diagnosed with AU had higher odds of legal blindness, and epiretinal membrane compared to non-White patients. Black and Hispanic patients were more likely to have glaucoma-related conditions at the time of AU diagnosis.

To investigate whether anterior uveitis developing after BNT162b2 COVID-19 vaccination-classified as Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)-exhibits distinct clinical features compared to idiopathic uveitis. This single-center retrospective study analyzed records of patients diagnosed with non-infectious anterior uveitis between June 1, 2021, and December 31, 2022. Patients were categorized into two groups: post-vaccine ASIA-related uveitis (Group 1) and idiopathic uveitis (Group 2). A total of 62 patients were included: 12 in Group 1 and 50 in Group 2. The mean age was similar (33.8 ± 10.4 vs. 35.1 ± 10.8 years; p = 0.547), with male predominance in both groups (61.1% vs. 58.5%). Group 1 had significantly milder anterior chamber inflammation (1.94 ± 0.64 vs. 2.85 ± 0.94; p < 0.001) and fewer ocular complications (16.7% vs. 60.0%; p = 0.003). All Group 1 cases responded to topical corticosteroids alone, while 32.3% in Group 2 required systemic immunosuppressants (p = 0.004). Best corrected visual acuity improved in both groups over time, but recovery was faster and more complete in Group 1 (p < 0.001 for time × group interaction). Anterior uveitis associated with ASIA syndrome post-vaccination appears to follow a milder, self-limiting course, with better visual outcomes and less aggressive treatment needs than idiopathic uveitis. These findings offer important insight into the clinical behavior of vaccine-associated ocular inflammation.

Pediatric uveitis is often asymptomatic, which may expose to sight-threatening ocular complications. The impact of modern medication on frequency of long-term ocular complications in pediatric patients with anterior idiopathic uveitis (idio-U) or juvenile idiopathic arthritis associated uveitis (JIA-U) is not fully understood. We aimed to evaluate the occurrence of ocular complications during the era of modern treatment on the population-based cohort of children with idio-U or JIA-U. A longitudinal, population-based cohort study of children with idio-U or JIA-U in 2008-2020. Variables assessed included age, gender, age at diagnosis, laterality, chronicity, vision, and ocular complications. 107 pediatric patients and 172 eyes with either idio-U (19 patients) or JIA-U (88 patients) were included. The mean age at uveitis onset was 10.0 ± 3.7 and 5.4 ± 3.2 years in idio-U and JIA-U, respectively (p < 0.001). Uveitis was chronic in 58% in idio-U and 74% in JIA-U patients, respectively. Uveitis was complicated with glaucoma in 45% of idio-U and 18% of JIA-U patients (p = 0.019). Cataract was developed in 31% of idio-U and 22% of JIA-U eyes (p = 0.28), and posterior synechiae in 21% and 9% of the eyes with idio-U and JIA-U, respectively. None of the eyes were hypotonic. Female gender was overrepresented in ocular complications. Glaucoma surgery was accomplished in 25 (15%) and cataract surgery in 19 (11%) eyes. Bilateral visual acuity remained > 0.5 in all patients. Glaucoma, ocular hypertension, and cataract were the most typical complications of uveitis. Complications occurred mostly in girls and in idio-U patients. JIA-U patients with severe uveitis, young age at uveitis onset and female gender were predisposing factors for surgical management.

Secukinumab is a monoclonal antibody that selectively neutralizes interleukin-17A and has shown efficacy in the treatment of psoriatic arthritis, psoriasis, and axial spondyloarthritis. Its use in non-anterior non-infectious uveitis is controversial, with evidence generally not supporting its effectiveness in these conditions. However, the role of secukinumab in anterior non-infectious uveitis remains unclear. Case series. Five patients with biological therapy-refractory non-infectious anterior uveitis who were treated with secukinumab were included. All 5 patients experienced a uveitis flare-up during treatment, and secukinumab failed to induce long-term remission in 2 of these patients, who also had uncontrolled systemic disease. Secukinumab failed to prevent uveitis flare-up in these patients with biological therapy-refractory disease. Further studies are necessary to determine the potential role of secukinumab in the treatment of anterior uveitis.